Taylor, Peter C. and Kavanaugh, Arthur and Nash, Peter and Pope, Janet and Pongratz, Georg and Fautrel, Bruno and Alten, Rieke and Hasegawa, Ken and Rao, Shangbang and de Vries, Dick and Stiers, Pieter-Jan and Watson, Chris and Westhovens, Rene (2024) Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD OPEN, 10 (1): e003839. ISSN 2056-5933
Full text not available from this repository. (Request a copy)Abstract
Objective This post hoc analysis of the FINCH 1-3 (NCT02889796, NCT02873936 and NCT02886728) studies assessed specific effects of filgotinib on pain control and their relationship with other aspects of efficacy in patients with rheumatoid arthritis (RA).Methods Assessments included: residual pain responses of <= 10 and <= 20 mm on a 100 mm visual analogue scale (VAS); the proportion of patients who achieved VAS pain responses in addition to remission or low disease activity by Disease Activity Score-28 with C-reactive protein (DAS28-CRP) or Clinical Disease Activity Index (CDAI) criteria.Results Across studies, filgotinib reduced pain from week 2, with responses sustained throughout the studies. In FINCH 1, at week 24, 35.8%, 25.0%, 24.6% and 11.6% of patients in the filgotinib 200 mg, filgotinib 100 mg, adalimumab and placebo arms (each plus methotrexate) achieved VAS pain <= 20 mm in addition to DAS28-CRP remission; 26.3%, 17.9%, 17.2% and 7.6% achieved VAS pain <= 10 mm in addition to DAS28-CRP remission. A similar pattern was seen for CDAI remission. Time during which VAS pain was <= 10 or <= 20 mm was longest with filgotinib 200 mg and comparable between adalimumab and filgotinib 100 mg. Similar findings were reported for filgotinib in FINCH 2 and 3.Conclusion In all RA populations studied, pain improvements occurred from week 2 and were sustained over time. In FINCH 1, filgotinib 100 mg provided similar pain amelioration to adalimumab, whereas filgotinib 200 mg resulted in greater pain improvement and higher proportion of patients with residual pain <= 10 or <= 20 mm and meeting DAS28-CRP remission criteria.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | EARLY RHEUMATOID-ARTHRITIS; DISEASE; MANAGEMENT; PATHWAY; ROLES; Antirheumatic Agents; Arthritis, Rheumatoid; Patient Reported Outcome Measures |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 15 Jan 2026 06:19 |
| Last Modified: | 15 Jan 2026 06:19 |
| URI: | https://pred.uni-regensburg.de/id/eprint/65196 |
Actions (login required)
 |
View Item |
